Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

被引：0
|
作者：
Ben Liao, John
Swensen, Ron E.
Reichow, Jessica
Ovenell, Kelsie J.
Childs, Jennifer
Higgins, Doreen
Buening, Barbara
Goff, Barbara Ann
Morishima, Chihiro
Disis, Mary L.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Valley Medcl Ctr, Renton, WA USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Univ Washington, Medcl Ctr, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5580
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, R. E.
    Childs, J.
    Higgins, D.
    Gooley, T.
    Goff, B. A.
    Fintak, P. A.
    Buening, B.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, Ron E.
    Goff, Barbara Ann
    Childs, Jennifer
    Higgins, Doreen
    Gooley, Theodore
    Fintak, Patricia A.
    Buening, Barbara
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study
    Coleman, R. L.
    Brady, W.
    McMeekin, D. S.
    Rose, P. G.
    Soper, J. T.
    Lentz, S. S.
    Hoffman, J. S.
    Shahin, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer
    Teneriello, M. G.
    Tseng, P. C.
    Crozier, M.
    Encarnacion, C.
    Hancock, K.
    Messing, M. J.
    Boehm, K. A.
    Williams, A.
    Ilegbodu, D.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    Tillmanns, T. D.
    Lowe, M. P.
    Schwartzberg, L. S.
    Walker, M. S.
    Stepanski, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
    Fu, S.
    Burger, R. A.
    Hamilton, E.
    Corr, B. R.
    Naumann, R. W.
    Wenham, R. M.
    Morgan, M. A.
    Stagg, R.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 14 - 15
  • [7] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [8] Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer
    Hendrickson, Andrea Elisabeth Wahner
    Foster, Nathan R.
    Clasemann, Tracy
    Grudem, Megan
    Klampe, Carolyn
    Block, Matthew Stephen
    Jatoi, Aminah
    Weroha, Saravut John
    Choong, Grace Mei Yee
    Yadav, Siddhartha
    Flickinger, Lynn M.
    Ashley, Gary W.
    Langecker, Peter J.
    Santi, Daniel V.
    Kaufmann, Scott H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial
    Cowan, Mathew
    Swetzig, Wendy M.
    Adorno-Cruz, Valery
    Pineda, Mario J.
    Neubauer, Nikki L.
    Berry, Emily
    Lurain, John R.
    Shahabi, Shohreh
    Taiym, Deanna
    Nelson, Valerie
    O'Shea, Kaitlyn Lucrezia
    Kocherginsky, Masha
    Matei, Daniela
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 57 - 63
  • [10] Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
    Dana M. Roque
    Eric R. Siegel
    Natalia Buza
    Stefania Bellone
    Dan-Arin Silasi
    Gloria S. Huang
    Vaagn Andikyan
    Mitchell Clark
    Masoud Azodi
    Peter E. Schwartz
    Gautam G. Rao
    Jocelyn C. Reader
    Pei Hui
    Joan R. Tymon-Rosario
    Justin Harold
    Dennis Mauricio
    Burak Zeybek
    Gulden Menderes
    Gary Altwerger
    Elena Ratner
    Alessandro D. Santin
    British Journal of Cancer, 2022, 126 : 1695 - 1703
12345